EP0395367B1 - Method for producing the XmaI restriction endonuclease - Google Patents

Method for producing the XmaI restriction endonuclease Download PDF

Info

Publication number
EP0395367B1
EP0395367B1 EP90304413A EP90304413A EP0395367B1 EP 0395367 B1 EP0395367 B1 EP 0395367B1 EP 90304413 A EP90304413 A EP 90304413A EP 90304413 A EP90304413 A EP 90304413A EP 0395367 B1 EP0395367 B1 EP 0395367B1
Authority
EP
European Patent Office
Prior art keywords
dna
xma
restriction endonuclease
restriction
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP90304413A
Other languages
German (de)
French (fr)
Other versions
EP0395367A1 (en
Inventor
Keith D. Lunnen
Geoffrey G. Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New England Biolabs Inc
Original Assignee
New England Biolabs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Biolabs Inc filed Critical New England Biolabs Inc
Publication of EP0395367A1 publication Critical patent/EP0395367A1/en
Application granted granted Critical
Publication of EP0395367B1 publication Critical patent/EP0395367B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1003Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007Methyltransferases (general) (2.1.1.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses

Definitions

  • the present invention relates to clones for the Xma I restriction endonuclease and modification methylase, and the production of the restriction enzyme from the clones.
  • Restriction endonucleases are a class of enzymes that occur naturally in bacteria. When they are purified away from other contaminating bacterial components, restriction endonucleases can be used in the laboratory to break DNA molecules into precise fragments. This property enables DNA molecules to be uniquely identified and to be fractionated into their constituent genes. Restriction endonucleases have proved to be indispensable tools in modern genetic research. They are the biochemical 'scissors' by means of which genetic engineering and analysis is performed.
  • Restriction endonucleases act by recognizing and binding to particular sequences of nucleotides (the 'recognition sequence') along the DNA molecule. Once bound, they cleave the molecule within, or to one side of, the sequence. Different restriction endonucleases have affinity for different recognition sequences. Over one hundred different restriction endonucleases have been identified among many hundreds of bacterial species that have been examined to date.
  • Bacteria tend to possess at most only a small number restriction endonucleases per species.
  • the endonucleases typically are named according to the bacteria from which they are derived.
  • the species Haemophilus aegyptius for example synthesizes 3 different restriction endonucleases, named Hae I, Hae II and Hae III.
  • These enzymes recognize and cleave the sequences (AT)GGCC(AT ),PuGCGCPy and GGCC respectively.
  • Escherichia coli RYl3 synthesizes only one enzyme, Eco RI, which recognizes the sequence GAATTC.
  • restriction endonucleases play a protective role in the welfare of the bacterial cell. They enable bacteria to resist infection by foreign DNA molecules like viruses and plasmids that would otherwise destroy or parasitize them. They impart resistance by scanning the lengths of the infecting DNA molecule and cleaving them each time that the recognition sequence occurs. The breakup that takes place disables many of the infecting genes and renders the DNA susceptible to further degradation by exonucleases.
  • a second component of bacterial protective systems are the modification methylases. These enzymes are complementary to restriction endonucleases and they provide the means by which bacteria are able to protect their own DNA and distinguish it from foreign, infecting DNA. Modification methylases recognize and bind to the same nucleotide recognition sequence as the corresponding restriction endonuclease, but instead of breaking the DNA, they chemically modify one or other of the nucleotides within the sequence by the addition of a methyl group. Following methylation, the recognition sequence is no longer bound or cleaved by the restriction endonuclease.
  • the DNA of a bacterial cell is always fully modified, by virtue of the activity of its modification methylase and it is therefore completely insensitive to the presence of the endogenous restriction endonuclease. It is only unmodified, and therefore identifiably foreign, DNA that is sensitive to restriction endonuclease recognition and attack.
  • the key to isolating clones of restriction endonuclease genes is to develop a simple and reliable method to identify such clones within complex 'libraries', i.e. populations of clones derived by 'shotgun' procedures, when they occur at frequencies as low as 10 -3 to 10 -4 .
  • the method should be selective, such that the unwanted, majority, of clones are destroyed while the desirable, rare, clones survive.
  • Type II restriction-modification systems are being cloned with increasing frequency.
  • the first cloned systems used bacteriophage infection as a means of identifying or selecting restriction endonuclease clones ( Eco RII: Kosykh et al., Molec. gen. Genet 178: 717-719, (1980); Hha II: Mann et al., Gene 3: 97-112, (1978); Pst I: Walder et al., Proc. Nat. Acad. Sci. 78 1503-1507, (1981)).
  • Another cloning approach involves transferring systems initially characterized as plasmid-borne into E. coli cloning plasmids ( Eco RV: Bougueleret et al., Nucl. Acid. Res. 12: 3659-3676, (1984); Pae R7: Gingeras and Brooks, Proc. Natl. Acad. Sci. USA 80: 402-406, (1983); Theriault and Roy, Gene 19: 355-359, (1982); Pvu II: Blumenthal et al., J. Bacteriol. 164: 501-509, (1985)).
  • a third approach and one that is being used to clone a growing number of systems, involves selecting for an active methylase gene, see for e.g., Bsu RI: Kiss et al., Nucl. Acid. Res. 13: 6403-6421, (1985); and Taq I: Slatko et al., Nucl. Acid. Res. 15: 9781-9796, (1987). Since restriction and modification genes tend to be closely linked, clones containing both genes can often be isolated by selecting for just the one gene.
  • a potential obstacle to cloning restriction-modification genes lies in trying to introduce the endonuclease gene into a host not already protected by modification. If the methylase gene and endonuclease gene are introduced together as a single clone, the methylase must protectively modify the host DNA before the endonuclease has the opportunity to cleave it. On occasion, therefore, it might only be possible to clone the genes sequentially, methylase first then endonuclease.
  • E. coli Another obstacle to cloning systems in E. coli was discovered in the process of cloning diverse methylase genes. Many E. coli strains (including those normally used in cloning) have systems that resist the introduction of DNA containing methylated cytosines. (Raleigh and Wilson, Proc. Natl. Acad. Sci., USA 83: 9070-9074, 1986). It is extremely difficult to clone cytosine-specific methylase genes, either alone, or together with their corresponding endonuclease gene, into these strains of E. coli . In order to clone these genes, therefore, it is necessary to use mutant strains of E. coli in which these systems are defective.
  • an isolated DNA segment coding for the XmaI restriction endonuclease an enzyme which recognizes the DNA sequence 5'-CCCGGG-3' and cleaves between C 1 and C 2 leaving a four nucleotide 5' overhang, wherein the isolated DNA segment is obtainable from a 10.3kb Hind III fragment of Xanthomonas malvacearum ATCC No. 9924.
  • the invention also provides a recombinant DNA vector comprising a vector into which a DNA segment according to the invention produced by a 10.3kb Hind III fragment of X. malvacearum ATCC No. 9924 has been inserted.
  • the invention further provides an isolated DNA segment coding for the XmaI restriction endonuclease, an enzyme which recognizes the DNA sequence 5'-CCCGGG-3' and cleaves between C 1 and C 2 leaving a four nucleotide 5' overhang, and methylase. wherein the isolated DNA segment is obtainable from a 10.3kb Hind III fragment of X. malvacearum ATCC No. 9924.
  • the invention also provides cloning vectors which comprise the isolated DNA segments of the invention together with host cells transformed by the vector of the invention.
  • the invention provides a method of producing Xma I restriction endonuclease comprising culturing a host cell of the invention transformed by a vector of the invention into which a DNA segment of the invention has been inserted under conditions for expression of said endonuclease.
  • Xma I restriction endonuclease produced in accordance with the present invention is substantially pure and free of the contaminants normally found in Xma I preparations made by conventional techniques.
  • the preferred method for cloning the genes for the Xma I enzymes comprises forming a library containing the DNA from X. malvacaerum, isolating those clones which contain DNA coding for the Xma I modification methylase and screening among these to identify those that also contain the Xma I restriction endonuclease gene.
  • the gene is obtainable from Xanthomonas malvacaerum (ATCC 9924) (Endow, S.A. and Roberts, R.J., J. Mol, Biol. 112: 521-529, (1997)).
  • Figure 1 illustrates the scheme for cloning and producing the Xma I restriction endonuclease.
  • Figure 2 is a restriction map of the pUC19 cloning vector derivative pKL19-2 which contains a second Xma I /Sma I site.
  • Figure 3 is a restriction map of a 10.3kb Hind III fragment insert encoding the Xma I restriction endonuclease and modification methylase.
  • Figure 4 is a photograph of an agarose gel illustrating Xma I restriction endonuclease activity obtained from the crude extract of pKL Xma IRM 102-2.
  • the present invention relates to clones of the Xma I restriction and modification genes, and to a method for producing restriction endonuclease Xma I from such clones.
  • the Xma I genes are cloned by a method which takes advantage of the fact that certain clones which are selected on the basis of containing and expressing the Xma I modification methylase gene also contain the Xma I restriction gene.
  • the DNA of such clones is resistant to digestion, in vitro, by the Xma I restriction endonuclease as well as the Sma I restriction endonuclease.
  • the Sma I restriction endonuclease is an isoschizomer of Xma I.
  • This resistance to digestion affords a means for selectively isolating clones encoding the Xma I methylase and restriction endonuclease.
  • DNA purification To prepare the DNA of Xanthomonas malvacearum (ATCC 9924), 5 g of frozen cells were thawed 1 hour on ice in 20 ml of 25% sucrose, 50mM Tris, pH 8.0 10 ml of 0.25M EDTA, pH 8 was added plus 6 ml 10mg/ml lysozyme in 0.25M Tris, pH 8.0. The suspension was incubated on ice 2 hours. To achieve cell lysis, 24 ml of lysis mix (1% TritonX-100, 50mM Tris, 62mM EDTA pH 5.0) and 5 ml 10% SDS were added.
  • lysis mix 1% TritonX-100, 50mM Tris, 62mM EDTA pH 5.0
  • the sample was extracted with 70 ml of phenol, (previously equilibrated with 0.5M Tris pH8.0), and then with 60 ml of Chloroform.
  • the emulsion was centrifuged at 10k rpm for 30 minutes.
  • the viscous upper layer was withdrawn and dialyzed for 24 hours against 10mM Tris, lmM EDTA, pH 8.0 (four buffer changes, 4 liters each).
  • the dialyzed solution was then digested with RNase at a final concentration of 100 microgram/ml for 1 hour at 37°C.
  • the DNA was then harvested by adding NaCl to a final concentration of 0.4M, overlaying with 0.55 volumes of isopropyl alcohol, and spooling DNA onto a glass rod by mixing the phases together.
  • the DNA was resuspended in 10mM Tris, 1 mM EDTA, pH 8.0 and stored at 4°C.
  • the digested DNA was ligated to pKL19-2 as follows: 6.0 ug of Hind III-digested X . malvacearum DNA (60 ul) was mixed with 3.0 ug of Hind III-cleaved and dephosphorylated pKL19-2 (7.5 ul). 20 ul of 10X ligation mix (500mM Tris, pH 7.5, 100mM MgCl 2 , 100mM DTT, 5mM ATP) was added, plus 112.5 ul of sterile distilled water to bring the final volume to 200 ul.
  • 10X ligation mix 500mM Tris, pH 7.5, 100mM MgCl 2 , 100mM DTT, 5mM ATP
  • E. coli strain RR1 7.5 ul of T4 DNA ligase was added and the mixture was incubated at 17°C for 4 hours, then sterilized by the addition of 10 ul of chloroform. Approximately 125 ul of the ligated DNA was used to transform E. coli strain RR1 as follows: The DNA was mixed with 1.0 ml of SSC/CaCl 2 (50mM NaCl, 5mM Na 3 Citrate, 67mM CaCl 2 ) on ice and 2.0 ml of ice-cold competent E. coli RR1 (hsd R - M - , ATCC No. 31343) cells were added. After a 5-minute incubation at 42°C, the cells were diluted by the addition of 8 ml of Luria-broth (L-broth) then incubated at 37°C for 4 hours.
  • L-broth Luria-broth
  • the primary plasmid library was prepared as follows: 2.5 ml of the primary cell library was inoculated into 500 ml of L-broth containing 100 ug/ml ampicillin. The culture was shaken overnight at 37°C then centrifuged at 4000 rpm for 5 minutes. The supernatant was discarded and the cell pellet was resuspended in 10 ml of 25% sucrose, 50mM Tris, pH 8.0, at room temperature. 5ml of 0.25M EDTA, pH 8.0, was added, followed by 3 ml of 10 mg/ml lysozyme in 0.25M Tris, pH 8.0.
  • the solution was left on ice for 1 hour, then 12 ml of lytic mix (1% Triton X-100, 50mM Tris, pH 8.0, 67mM EDTA) was forcefully pipetted in, and the cell suspension was gently swirled to achieve lysis. After lysis, the mixture was transferred to a 50 ml plastic centrifuge tube and spun at 17000 rpm, 4°C for 45 minutes. The supernatant was removed with a pipette. 20.0 gm of solid CsCl was weighed into a 50 ml plastic screw-cap tube and 22.0 gm of supernatant was pipetted into the tube and mixed.
  • lytic mix 1% Triton X-100, 50mM Tris, pH 8.0, 67mM EDTA
  • ethidium bromide solution 5 mg/ml ethidium bromide in 10mM Tris, pH 8.0, 1mM EDTA, 100mM NaCl was added to the mixture.
  • the solution was transferred to two 5/8 in. x 3 in. polyallomer centrifuge tubes and sealed. These tubes were then spun in a Beckman Ti70 rotor for 42 hours at 44000 rpm, 17°C.
  • the tubes were illuminated with ultraviolet light, the tops were pierced with a scalpel and the lower of the two fluorescent DNA bands was collected by syringe.
  • the lower band from each tube was combined into a screw-top glass tube and the ethidium bromide was removed by extracting 4 times with an equal volume of water-saturated ice-cold N-Butanol.
  • the extracted solution was transferred to dialysis tubing and dialyzed for 24 hours against 4 changes of DNA buffer (10mM Tris pH 7.5, 1mM EDTA).
  • the dialyzed DNA solution was then transferred to a pre-weighed 50 ml sterile centrifuge tube and its volume was measured. 5M NaCl was added to a final concentration of 0.4M, then 2 volumes of isopropanol were added and mixed.
  • the solution was stored overnight at -20°C to precipitate the DNA. After precipitation, the solution was spun at 15000 rpm, 0°C for 15 minutes and the supernatant was discarded. The tube was left on the bench to air-dry for 15 minutes, then the DNA pellet was dissolved in 500 ul of DNA buffer and stored at -20°C.
  • the DNA concentration of plasmid libraries prepared in this way was found to be -100 to 200 ug/ml.
  • the primary plasmid pool was digested to destroy non- Xma I methylase clones as follows: 0.5 ug of the plasmid library in 90 ul of Sma I-digestion buffer (6mM Tris.HCl, pH 8.0, 6mM MgCl 2 , 6mM 2-mercaptoethanol, 20mM KCl) was incubated with 20 units (2 ul) of SmaI restriction enzyme at 25°C for 2h. The digested DNA was chloroform-extracted and microfuged.
  • Sma I-digestion buffer 6mM Tris.HCl, pH 8.0, 6mM MgCl 2 , 6mM 2-mercaptoethanol, 20mM KCl
  • Transformation A 12.5 ul sample from the tube was used to transform 200 ul of competent E. coli RR1. The cell/DNA mixtures were plated onto L-agar plates containing 100 ug/ml ampicillin. After overnight incubation at 37°C, the plates were examined. Digestion of the plasmid library with Sma I was found to have reduced the number of transformants by a factor greater than 10 4 . Individual colonies were picked from the plate and each was inoculated into 10 ml of L-broth containing ampicillin, to prepare a miniculture, and was also streaked onto L-agar plates containing ampicillin to prepare a master stock.
  • each supernatant was poured into a centrifuge tube containing 3 ml of isopropanol and mixed. After 10 minutes at room temperature, the tubes were spun at 15000 rpm for 10 minutes to pellet the precipitated nucleic acids. The supernatants were discarded and the pellets were air-dried at room temperature for 30 minutes. Once dry, the pellets were resuspended in 850 ul of 10mM Tris, 1mM EDTA, pH 8.0. 75 ul of 5M NaCl was added to each and the solutions were transferred to Eppendorf tubes containing 575 ul of isopropanol, and again precipitated for 10 minutes at room temperature.
  • the tubes were then spun for 45 seconds in a microfuge, the supernatants were discarded and the pellets were air-dried.
  • the pellets were then dissolved in 500 ul of 10mM Tris, 1mM EDTA, pH 8.0, containing 100 ug/ml RNase and incubated for 1 hour at 37°C to digest the RNA.
  • the DNA was precipitated once more by the addition of 50 ul of 5M NaCl followed by 350ul of isopropanol. After 10 minutes at room temperature, the DNA was spun down by centrifugation for 45 seconds, the supernatants were discarded and the pellets were redissolved in a final solution of 150 ul of 10mM Tris 1mM EDTA, pH 8.0.
  • the plasmid minipreps were subsequently analyzed by digestion with Xma I.
  • Xma I Methylase Gene Clones Seventeen of the plasmids that were analyzed were found to be fully resistant to digestion by the Xma I restriction enzyme. The clones carried one Hind III fragment of approximately 10.3kb in length. (See Figure 3). These plasmids appeared to be identical and were subsequently shown to carry not only the XmaI modification methylase gene but also the Xma I restriction endonuclease gene.
  • Xma I Restriction Gene Clone One of the plasmids, designated pKLXmaIRM 102-2, identified above (section 9) as carrying the Xma I modification methylase gene was also found to carry the Xma I restriction endonuclease gene. This was established by an in vitro restriction endonuclease assay of an extract prepared from E. coli strain K802 (ATCC 33526) into which the plasmid had been transferred by transformation.
  • Endonuclease Assays To assay for endonuclease activity, two solutions were prepared:
  • the cell extract was prepared as follows: A 100 ml culture of the clone was grown overnight in L-broth plus 100 ug/ml ampicillin at 37°C and the cells were pelleted by centrifugation at 4000 rpm for 5 minutes. The supernatant was discarded and the pellet was resuspended in 3 ml of sonication buffer (50mM KPO 4 pH 7.5, 10mM BME, 0.1mM EDTA). 0.3 ml of sonication buffer containing 10 mg/ml lysozyme was added, the suspension was swirled and then left on ice for 1 hour.
  • sonication buffer 50mM KPO 4 pH 7.5, 10mM BME, 0.1mM EDTA
  • a 1 ml sample was transferred to an Eppendorf tube and sonicated gently for three 10-second bursts to disrupt the cells. The tube was spun for 5 minutes in a microfuge and the supernatant was used as the cell extract. To assay the extract, the digestion reaction mix was dispensed into 5 tubes, 150 ul into the first tube and 100 ul into each of the remaining 4 tubes. 7.5 ul of the extract was added to the first tube and mixed. 47.5 ul was removed from the first tube and transferred to the second tube, mixed and so on. The first tube thus received 1.0 ul of extract per ug of DNA, the second tube 0.3 ul/ug, the third tube, 0.1 ul/ug and so on.
  • the titre of the extract was found to be approximately 1x10 3 units per ml, which corresponds to about 1 to 2x10 5 units of Xma I restriction endonuclease per gram of cells. (See Figure 4).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Description

BACKGROUND OF THE INVENTION
The present invention relates to clones for the XmaI restriction endonuclease and modification methylase, and the production of the restriction enzyme from the clones.
Restriction endonucleases are a class of enzymes that occur naturally in bacteria. When they are purified away from other contaminating bacterial components, restriction endonucleases can be used in the laboratory to break DNA molecules into precise fragments. This property enables DNA molecules to be uniquely identified and to be fractionated into their constituent genes. Restriction endonucleases have proved to be indispensable tools in modern genetic research. They are the biochemical 'scissors' by means of which genetic engineering and analysis is performed.
Restriction endonucleases act by recognizing and binding to particular sequences of nucleotides (the 'recognition sequence') along the DNA molecule. Once bound, they cleave the molecule within, or to one side of, the sequence. Different restriction endonucleases have affinity for different recognition sequences. Over one hundred different restriction endonucleases have been identified among many hundreds of bacterial species that have been examined to date.
Bacteria tend to possess at most only a small number restriction endonucleases per species. The endonucleases typically are named according to the bacteria from which they are derived. Thus, the species Haemophilus aegyptius, for example synthesizes 3 different restriction endonucleases, named HaeI, HaeII and HaeIII. These enzymes recognize and cleave the sequences (AT)GGCC(AT ),PuGCGCPy and GGCC respectively. Escherichia coli RYl3, on the other hand, synthesizes only one enzyme, EcoRI, which recognizes the sequence GAATTC.
While not wishing to be bound by theory, it is thought that in nature, restriction endonucleases play a protective role in the welfare of the bacterial cell. They enable bacteria to resist infection by foreign DNA molecules like viruses and plasmids that would otherwise destroy or parasitize them. They impart resistance by scanning the lengths of the infecting DNA molecule and cleaving them each time that the recognition sequence occurs. The breakup that takes place disables many of the infecting genes and renders the DNA susceptible to further degradation by exonucleases.
A second component of bacterial protective systems are the modification methylases. These enzymes are complementary to restriction endonucleases and they provide the means by which bacteria are able to protect their own DNA and distinguish it from foreign, infecting DNA. Modification methylases recognize and bind to the same nucleotide recognition sequence as the corresponding restriction endonuclease, but instead of breaking the DNA, they chemically modify one or other of the nucleotides within the sequence by the addition of a methyl group. Following methylation, the recognition sequence is no longer bound or cleaved by the restriction endonuclease. The DNA of a bacterial cell is always fully modified, by virtue of the activity of its modification methylase and it is therefore completely insensitive to the presence of the endogenous restriction endonuclease. It is only unmodified, and therefore identifiably foreign, DNA that is sensitive to restriction endonuclease recognition and attack.
With the advent of genetic engineering technology, it is now possible to clone genes and to produce the proteins and enzymes that they encode in greater quantities than are obtainable by conventional purification techniques. The key to isolating clones of restriction endonuclease genes is to develop a simple and reliable method to identify such clones within complex 'libraries', i.e. populations of clones derived by 'shotgun' procedures, when they occur at frequencies as low as 10-3 to 10-4. Preferably, the method should be selective, such that the unwanted, majority, of clones are destroyed while the desirable, rare, clones survive.
Type II restriction-modification systems are being cloned with increasing frequency. The first cloned systems used bacteriophage infection as a means of identifying or selecting restriction endonuclease clones (EcoRII: Kosykh et al., Molec. gen. Genet 178: 717-719, (1980); HhaII: Mann et al., Gene 3: 97-112, (1978); PstI: Walder et al., Proc. Nat. Acad. Sci. 78 1503-1507, (1981)). Since the presence of restriction-modification systems in bacteria enables them to resist infection by bacteriophages, cells that carry cloned restriction-modification genes can, in principle, be selectively isolated as survivors from libraries that have been exposed to phage. This method has been found, however, to have only limited value. Specifically, it has been found that cloned restriction-modification genes do not always manifest sufficient phage resistance to confer selective survival.
Another cloning approach involves transferring systems initially characterized as plasmid-borne into E. coli cloning plasmids (EcoRV: Bougueleret et al., Nucl. Acid. Res. 12: 3659-3676, (1984); PaeR7: Gingeras and Brooks, Proc. Natl. Acad. Sci. USA 80: 402-406, (1983); Theriault and Roy, Gene 19: 355-359, (1982); PvuII: Blumenthal et al., J. Bacteriol. 164: 501-509, (1985)).
A third approach, and one that is being used to clone a growing number of systems, involves selecting for an active methylase gene, see for e.g., BsuRI: Kiss et al., Nucl. Acid. Res. 13: 6403-6421, (1985); and TaqI: Slatko et al., Nucl. Acid. Res. 15: 9781-9796, (1987). Since restriction and modification genes tend to be closely linked, clones containing both genes can often be isolated by selecting for just the one gene. Selection for methylation activity does not always yield a complete restriction-modification system however, but instead sometimes yields only the methylase gene (BspRI: Szomolanyi et al., Gene 10: 219-225, (1980); BcnI: Janulaitis et al, Gene 20: 197-204, (1982); BsuRI: Kiss and Baldauf, Gene 21: 111-119, (1983); and MspI: Walder et al., J. Biol. Chem. 258: 1235-1241, (1983)). For an overall review of cloning restriction-modification systems see for e.g., Lunnen et al, Gene 74: 25-32, (1988); and Wilson, G.G., Gene 74: 281-289, (1988).
A potential obstacle to cloning restriction-modification genes lies in trying to introduce the endonuclease gene into a host not already protected by modification. If the methylase gene and endonuclease gene are introduced together as a single clone, the methylase must protectively modify the host DNA before the endonuclease has the opportunity to cleave it. On occasion, therefore, it might only be possible to clone the genes sequentially, methylase first then endonuclease.
Another obstacle to cloning systems in E. coli was discovered in the process of cloning diverse methylase genes. Many E. coli strains (including those normally used in cloning) have systems that resist the introduction of DNA containing methylated cytosines. (Raleigh and Wilson, Proc. Natl. Acad. Sci., USA 83: 9070-9074, 1986). It is extremely difficult to clone cytosine-specific methylase genes, either alone, or together with their corresponding endonuclease gene, into these strains of E. coli. In order to clone these genes, therefore, it is necessary to use mutant strains of E. coli in which these systems are defective.
Because purified restriction endonucleases, and to a lesser extent, modification methylases, are useful tools for characterizing and rearranging DNA in the laboratory, there is a commercial incentive to obtain strains of bacteria through recombinant DNA techniques that synthesize these enzymes in abundance. Such strains would be useful because they would simplify the task of purification as well as providing the means for production in commercially useful amounts.
SUMMARY OF THE INVENTION
In accordance with the present invention there is provided an isolated DNA segment coding for the XmaI restriction endonuclease, an enzyme which recognizes the DNA sequence 5'-CCCGGG-3' and cleaves between C1 and C2 leaving a four nucleotide 5' overhang, wherein the isolated DNA segment is obtainable from a 10.3kb HindIII fragment of Xanthomonas malvacearum ATCC No. 9924. The invention also provides a recombinant DNA vector comprising a vector into which a DNA segment according to the invention produced by a 10.3kb HindIII fragment of X. malvacearum ATCC No. 9924 has been inserted. The invention further provides an isolated DNA segment coding for the XmaI restriction endonuclease, an enzyme which recognizes the DNA sequence 5'-CCCGGG-3' and cleaves between C1 and C2 leaving a four nucleotide 5' overhang, and methylase. wherein the isolated DNA segment is obtainable from a 10.3kb HindIII fragment of X. malvacearum ATCC No. 9924. The invention also provides cloning vectors which comprise the isolated DNA segments of the invention together with host cells transformed by the vector of the invention. Additionally the invention provides a method of producing XmaI restriction endonuclease comprising culturing a host cell of the invention transformed by a vector of the invention into which a DNA segment of the invention has been inserted under conditions for expression of said endonuclease. XmaI restriction endonuclease produced in accordance with the present invention is substantially pure and free of the contaminants normally found in XmaI preparations made by conventional techniques.
The preferred method for cloning the genes for the XmaI enzymes comprises forming a library containing the DNA from X. malvacaerum, isolating those clones which contain DNA coding for the XmaI modification methylase and screening among these to identify those that also contain the XmaI restriction endonuclease gene. The gene is obtainable from Xanthomonas malvacaerum (ATCC 9924) (Endow, S.A. and Roberts, R.J., J. Mol, Biol. 112: 521-529, (1997)).
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 illustrates the scheme for cloning and producing the XmaI restriction endonuclease.
Figure 2 is a restriction map of the pUC19 cloning vector derivative pKL19-2 which contains a second XmaI/SmaI site.
Figure 3 is a restriction map of a 10.3kb HindIII fragment insert encoding the XmaI restriction endonuclease and modification methylase.
Figure 4 is a photograph of an agarose gel illustrating XmaI restriction endonuclease activity obtained from the crude extract of pKLXmaIRM 102-2.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to clones of the XmaI restriction and modification genes, and to a method for producing restriction endonuclease XmaI from such clones. The XmaI genes are cloned by a method which takes advantage of the fact that certain clones which are selected on the basis of containing and expressing the XmaI modification methylase gene also contain the XmaI restriction gene. The DNA of such clones is resistant to digestion, in vitro, by the XmaI restriction endonuclease as well as the SmaI restriction endonuclease. (The SmaI restriction endonuclease is an isoschizomer of XmaI.) This resistance to digestion affords a means for selectively isolating clones encoding the XmaI methylase and restriction endonuclease.
The method described herein by which the XmaI restriction gene and methylase gene can be cloned and expressed is illustrated in Figure 1, and includes the following steps:
  • 1. The growth and lysis of X. malvacearum (ATCC 9924). X. malvacearum is grown and lysed in accordance with techniques described by Endow et al.
  • 2. The DNA of X. malvacearum is purified by standard techniques such as, phenol and chloroform extraction, dialysis, and isopropanol precipitation.
  • 3. The DNA is digested partially with either of the restriction endonucleases HindIII, BamHI and EcoRI.
  • 4. The digested DNA is ligated into a cloning vector, such as a pBR322 derivative containing a BamHI, HindIII or EcoRI site. XmaI clones were obtained using pKL19-2 as the cloning vector. pKL19-2 is pUC19 to which a second XmaI/SmaI site was inserted, replacing the DNA between DraI sites at nucleotides 1563 and 1582, using an 8-bp phosphorylated linker, d(pCCCCGGGG). (A sample of pKL19-2 is desposited in the ATCC under ATCC number 67997 ). The resulting mixture is used to transform an appropriate host such as E. coli strain RR1 (ATCC 31343).
  • 5. The DNA/cell mixture is plated on antibiotic media selective for transformed cells, such as ampicillin. After incubation, the transformed cell colonies are collected together into a single culture, the primary cell library.
  • 6. The recombinant plasmids are purified in toto from the primary cell library to make a primary plasmid library.
  • 7. The plasmid library is then digested to completion in vitro with the SmaI restriction endonuclease, which was prepared from Serratia marcescens cells (Endow et al.) by standard protein purification techniques such as affinity-chromatography and ion-exchange chromatography. XmaI-methylated DNA is resistant to digestion by both XmaI and SmaI restriction endonucleases. Digestion causes the selective destruction of unmodified, non-methylase-containing clones, resulting in an increase in the relative frequency of XmaI methylase-carrying clones. SmaI restriction endonuclease recognizes the same sequence as XmaI, but cuts between C3 and G1 in the sequence 5'-CCCGGG-3' leaving blunt ends. Cleaved, blunt-ended molecules are less likely to resume circularity upon transformation; SmaI digestion of the primary library is therefore probably more selective for modified molecules than is XmaI digestion.
  • 8. The digested plasmid library DNA is transformed back into an appropriate host, such as E.coli strain RR1, and transformed colonies are again obtained by plating on antibiotic plates. The colonies are picked and their DNA is analyzed for the presence of the XmaI modification gene in the following manner: The plasmid DNA that they carry is purified and incubated in vitro with XmaI restriction endonuclease to determine whether it is resistant to digestion by XmaI. The total cellular DNA (chromosomal and plasmid) of the clone is also purified and incubated with XmaI restriction endonuclease. The DNA of clones that carry the XmaI methylase gene should be modified, and both the plasmid DNA and the total DNA should be found to be substantially, or completely resistant to digestion.
  • 9. Clones carrying the XmaI restriction endonuclease are identified by preparing crude extracts of those clones identified in step 8 as carrying the XmaI methylase gene, and assaying the extracts for XmaI restriction endonuclease activity.
  • 10. The XmaI restriction endonuclease may be produced from clones carrying the XmaI restriction and modification genes by propagation in a fermenter in a rich medium containing ampicillin. The cells are thereafter harvested by centrifugation and disrupted by sonication to produce a crude cell extract containing the XmaI restriction endonuclease activity.
  • 11. The crude cell extract containing the XmaI restriction endonuclease activity is purified by standard protein purification techniques such as affinity-chromatography, and ion-exchange chromatography.
  • The following example is given to illustrate an embodiment of the present invention.
    EXAMPLE Cloning of XmaI Restriction Endonuclease Gene
    1. DNA purification: To prepare the DNA of Xanthomonas malvacearum (ATCC 9924), 5 g of frozen cells were thawed 1 hour on ice in 20 ml of 25% sucrose, 50mM Tris, pH 8.0 10 ml of 0.25M EDTA, pH 8 was added plus 6 ml 10mg/ml lysozyme in 0.25M Tris, pH 8.0. The suspension was incubated on ice 2 hours. To achieve cell lysis, 24 ml of lysis mix (1% TritonX-100, 50mM Tris, 62mM EDTA pH 5.0) and 5 ml 10% SDS were added. The sample was extracted with 70 ml of phenol, (previously equilibrated with 0.5M Tris pH8.0), and then with 60 ml of Chloroform. The emulsion was centrifuged at 10k rpm for 30 minutes. The viscous upper layer was withdrawn and dialyzed for 24 hours against 10mM Tris, lmM EDTA, pH 8.0 (four buffer changes, 4 liters each). The dialyzed solution was then digested with RNase at a final concentration of 100 microgram/ml for 1 hour at 37°C. The DNA was then harvested by adding NaCl to a final concentration of 0.4M, overlaying with 0.55 volumes of isopropyl alcohol, and spooling DNA onto a glass rod by mixing the phases together. The DNA was resuspended in 10mM Tris, 1 mM EDTA, pH 8.0 and stored at 4°C.
    2. Digestion of DNA: The purified DNA was cleaved partially with HindIII. DNA was diluted to a concentration of 100 micrograms per ml in 50mM Tris pH 7.5, 100mM NaCl, 10mM MgCl2, 10mM 2-mercaptoethanol, and 4.0 units of HindIII per microgram of DNA was added to a first tube and then transferred to a second tube to achieve 2.0 units of HindIII/ug and so on, each succeeding tube receiving half of the previous amount of enzyme. The DNA was digested for one hour at 37°C, then the digestions were terminated by heating to 72°C for 10 minutes. Tubes exhibiting moderate, but incomplete digestion were chosen as the source of partial digest fragments for cloning. (These were the 0.5 u/ug, 0.25 u/ug, 0.1 u/ug, .05 u/ug, and .02 u/ug tubes. The five solutions were mixed together and used as described below.)
    3. Ligation: The digested DNA was ligated to pKL19-2 as follows: 6.0 ug of HindIII-digested X. malvacearum DNA (60 ul) was mixed with 3.0 ug of HindIII-cleaved and dephosphorylated pKL19-2 (7.5 ul). 20 ul of 10X ligation mix (500mM Tris, pH 7.5, 100mM MgCl2, 100mM DTT, 5mM ATP) was added, plus 112.5 ul of sterile distilled water to bring the final volume to 200 ul. 7.5 ul of T4 DNA ligase was added and the mixture was incubated at 17°C for 4 hours, then sterilized by the addition of 10 ul of chloroform. Approximately 125 ul of the ligated DNA was used to transform E. coli strain RR1 as follows: The DNA was mixed with 1.0 ml of SSC/CaCl2 (50mM NaCl, 5mM Na3 Citrate, 67mM CaCl2) on ice and 2.0 ml of ice-cold competent E. coli RR1 (hsd R-M-, ATCC No. 31343) cells were added. After a 5-minute incubation at 42°C, the cells were diluted by the addition of 8 ml of Luria-broth (L-broth) then incubated at 37°C for 4 hours.
    4. Primary Cell Library: The transformed cell culture was briefly centrifuged, the supernatant was discarded and the cells were resuspended in 1.0 ml of L-broth. 200 ul portions were plated onto Luria-agar (L-agar) plates containing 100 ug/ml ampicillin. After overnight incubation at 37°C, the plates were each flooded with 2.5 ml of 10 mM Tris, pH 7.5, 10mM MgCl2 and the transformed colonies were scraped together and pooled to form the primary cell library.
    5. Primary Plasmid Library: The primary plasmid library was prepared as follows: 2.5 ml of the primary cell library was inoculated into 500 ml of L-broth containing 100 ug/ml ampicillin. The culture was shaken overnight at 37°C then centrifuged at 4000 rpm for 5 minutes. The supernatant was discarded and the cell pellet was resuspended in 10 ml of 25% sucrose, 50mM Tris, pH 8.0, at room temperature. 5ml of 0.25M EDTA, pH 8.0, was added, followed by 3 ml of 10 mg/ml lysozyme in 0.25M Tris, pH 8.0. The solution was left on ice for 1 hour, then 12 ml of lytic mix (1% Triton X-100, 50mM Tris, pH 8.0, 67mM EDTA) was forcefully pipetted in, and the cell suspension was gently swirled to achieve lysis. After lysis, the mixture was transferred to a 50 ml plastic centrifuge tube and spun at 17000 rpm, 4°C for 45 minutes. The supernatant was removed with a pipette. 20.0 gm of solid CsCl was weighed into a 50 ml plastic screw-cap tube and 22.0 gm of supernatant was pipetted into the tube and mixed. 1.0 ml of ethidium bromide solution (5 mg/ml ethidium bromide in 10mM Tris, pH 8.0, 1mM EDTA, 100mM NaCl) was added to the mixture. The solution was transferred to two 5/8 in. x 3 in. polyallomer centrifuge tubes and sealed. These tubes were then spun in a Beckman Ti70 rotor for 42 hours at 44000 rpm, 17°C. To collect the plasmids, the tubes were illuminated with ultraviolet light, the tops were pierced with a scalpel and the lower of the two fluorescent DNA bands was collected by syringe. The lower band from each tube was combined into a screw-top glass tube and the ethidium bromide was removed by extracting 4 times with an equal volume of water-saturated ice-cold N-Butanol.
    The extracted solution was transferred to dialysis tubing and dialyzed for 24 hours against 4 changes of DNA buffer (10mM Tris pH 7.5, 1mM EDTA). The dialyzed DNA solution was then transferred to a pre-weighed 50 ml sterile centrifuge tube and its volume was measured. 5M NaCl was added to a final concentration of 0.4M, then 2 volumes of isopropanol were added and mixed. The solution was stored overnight at -20°C to precipitate the DNA. After precipitation, the solution was spun at 15000 rpm, 0°C for 15 minutes and the supernatant was discarded. The tube was left on the bench to air-dry for 15 minutes, then the DNA pellet was dissolved in 500 ul of DNA buffer and stored at -20°C. The DNA concentration of plasmid libraries prepared in this way was found to be -100 to 200 ug/ml.
    6. Digestion of Plasmid Pool: The primary plasmid pool was digested to destroy non-XmaI methylase clones as follows: 0.5 ug of the plasmid library in 90 ul of SmaI-digestion buffer (6mM Tris.HCl, pH 8.0, 6mM MgCl2, 6mM 2-mercaptoethanol, 20mM KCl) was incubated with 20 units (2 ul) of SmaI restriction enzyme at 25°C for 2h. The digested DNA was chloroform-extracted and microfuged.
    7. Transformation: A 12.5 ul sample from the tube was used to transform 200 ul of competent E. coli RR1. The cell/DNA mixtures were plated onto L-agar plates containing 100 ug/ml ampicillin. After overnight incubation at 37°C, the plates were examined. Digestion of the plasmid library with SmaI was found to have reduced the number of transformants by a factor greater than 104. Individual colonies were picked from the plate and each was inoculated into 10 ml of L-broth containing ampicillin, to prepare a miniculture, and was also streaked onto L-agar plates containing ampicillin to prepare a master stock.
    8. Analysis of surviving individuals: Twenty-nine of the surviving colonies obtained from section 8 were grown up into 10 ml cultures (section 7) and the plasmids that they carried were prepared by the following miniprep purification procedure, adapted from the method of Birnboin and Doly (Nucleic Acids Res. 7: 1513, (1979)).
    Miniprep Procedure: Each culture was centrifuged at 8000 rpm for 5 minutes; the supernatant was discarded and the cell pellet was resuspended in 1.0 ml of 25mM Tris, 10mM EDTA, 50mM glucose, pH 8.0, containing 1 mg/ml lysozyme. After 10 minutes at room temperature, 2.0 ml of 0.2M NaOH, 1% SDS was added to each tube and the tubes were shaken to lyse the cells, then placed on ice. Once the solutions had cleared, 1.5 ml of 3M sodium acetate, pH 4.8, was added to each and shaken. The precipitates that formed were spun down at 15000 rpm, 4°C for 10 minutes. Each supernatant was poured into a centrifuge tube containing 3 ml of isopropanol and mixed. After 10 minutes at room temperature, the tubes were spun at 15000 rpm for 10 minutes to pellet the precipitated nucleic acids. The supernatants were discarded and the pellets were air-dried at room temperature for 30 minutes. Once dry, the pellets were resuspended in 850 ul of 10mM Tris, 1mM EDTA, pH 8.0. 75 ul of 5M NaCl was added to each and the solutions were transferred to Eppendorf tubes containing 575 ul of isopropanol, and again precipitated for 10 minutes at room temperature. The tubes were then spun for 45 seconds in a microfuge, the supernatants were discarded and the pellets were air-dried. The pellets were then dissolved in 500 ul of 10mM Tris, 1mM EDTA, pH 8.0, containing 100 ug/ml RNase and incubated for 1 hour at 37°C to digest the RNA. The DNA was precipitated once more by the addition of 50 ul of 5M NaCl followed by 350ul of isopropanol. After 10 minutes at room temperature, the DNA was spun down by centrifugation for 45 seconds, the supernatants were discarded and the pellets were redissolved in a final solution of 150 ul of 10mM Tris 1mM EDTA, pH 8.0. The plasmid minipreps were subsequently analyzed by digestion with XmaI.
    9. XmaI Methylase Gene Clones: Seventeen of the plasmids that were analyzed were found to be fully resistant to digestion by the XmaI restriction enzyme. The clones carried one HindIII fragment of approximately 10.3kb in length. (See Figure 3). These plasmids appeared to be identical and were subsequently shown to carry not only the XmaI modification methylase gene but also the XmaI restriction endonuclease gene.
    10. XmaI Restriction Gene Clone: One of the plasmids, designated pKLXmaIRM 102-2, identified above (section 9) as carrying the XmaI modification methylase gene was also found to carry the XmaI restriction endonuclease gene. This was established by an in vitro restriction endonuclease assay of an extract prepared from E. coli strain K802 (ATCC 33526) into which the plasmid had been transferred by transformation.
    Endonuclease Assays: To assay for endonuclease activity, two solutions were prepared:
  • (i) 10X restriction endonuclease buffer: 100mM Tris, pH 7.5, 100mM MgCl2, 100mM 2-mercaptoethanol, 500mM NaCl; and (ii) digestion reaction mix: 55 ul HindIII-digested Lambda DNA (500ug/ml), 55 ul 10X restriction endonuclease buffer, 440 ul distilled water to achieve 50ug/ml DNA.
  • The cell extract was prepared as follows: A 100 ml culture of the clone was grown overnight in L-broth plus 100 ug/ml ampicillin at 37°C and the cells were pelleted by centrifugation at 4000 rpm for 5 minutes. The supernatant was discarded and the pellet was resuspended in 3 ml of sonication buffer (50mM KPO4 pH 7.5, 10mM BME, 0.1mM EDTA). 0.3 ml of sonication buffer containing 10 mg/ml lysozyme was added, the suspension was swirled and then left on ice for 1 hour. A 1 ml sample was transferred to an Eppendorf tube and sonicated gently for three 10-second bursts to disrupt the cells. The tube was spun for 5 minutes in a microfuge and the supernatant was used as the cell extract. To assay the extract, the digestion reaction mix was dispensed into 5 tubes, 150 ul into the first tube and 100 ul into each of the remaining 4 tubes. 7.5 ul of the extract was added to the first tube and mixed. 47.5 ul was removed from the first tube and transferred to the second tube, mixed and so on. The first tube thus received 1.0 ul of extract per ug of DNA, the second tube 0.3 ul/ug, the third tube, 0.1 ul/ug and so on. The tubes, each now containing 100 ul, were incubated at 37°C for one hour, then a 20 ul sample of each was analyzed by gel electrophoresis. The titre of the extract was found to be approximately 1x103 units per ml, which corresponds to about 1 to 2x105 units of XmaI restriction endonuclease per gram of cells. (See Figure 4).

    Claims (7)

    1. Isolated DNA segment coding for the XmaI restriction endonuclease, an enzyme which recognizes the DNA sequence 5'-CCCGGG-3' and cleaves between C1 and C2 leaving a four nucleotide 5' overhang, wherein the isolated DNA segment is obtainable from a 10.3kb HindIII fragment of Xanthomonas malvacearum ATCC No. 9924.
    2. A recombinant DNA vector comprising a vector into which a DNA segment according to claim 1 produced by a 10.3kb HindIII fragment of X. malvacearum ATCC No. 9924 has been inserted.
    3. Isolated DNA segment coding for the XmaI restriction endonuclease, an enzyme which recognizes the DNA sequence 5'-CCCGGG-3' and cleaves between C1 and C2 leaving a four nucleotide 5' overhang, and methylase, wherein the isolated DNA segment is obtainable from a 10.3kb HindIII fragment of X. malvacearum ATCC No. 9924.
    4. A cloning vector which comprises the isolated DNA segment according to claim 1.
    5. A cloning vector which comprises the isolated DNA segment according to claim 3.
    6. A host cell transformed by the vector according to claim 4 or 5.
    7. A method of producing Xmal restriction endonuclease comprising culturing the transformed host cell of claim 6 under conditions for expression of said endonuclease.
    EP90304413A 1989-04-27 1990-04-25 Method for producing the XmaI restriction endonuclease Expired - Lifetime EP0395367B1 (en)

    Applications Claiming Priority (2)

    Application Number Priority Date Filing Date Title
    US07/344,268 US5002882A (en) 1989-04-27 1989-04-27 Method for producing the XmaI restriction endonuclease and methylase
    US344268 1989-04-27

    Related Child Applications (1)

    Application Number Title Priority Date Filing Date
    EP97201672 Division 1997-06-03

    Publications (2)

    Publication Number Publication Date
    EP0395367A1 EP0395367A1 (en) 1990-10-31
    EP0395367B1 true EP0395367B1 (en) 1998-09-09

    Family

    ID=23349779

    Family Applications (1)

    Application Number Title Priority Date Filing Date
    EP90304413A Expired - Lifetime EP0395367B1 (en) 1989-04-27 1990-04-25 Method for producing the XmaI restriction endonuclease

    Country Status (4)

    Country Link
    US (1) US5002882A (en)
    EP (1) EP0395367B1 (en)
    JP (1) JP2952003B2 (en)
    DE (2) DE395367T1 (en)

    Families Citing this family (55)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US5298404A (en) * 1989-10-13 1994-03-29 New England Biolabs, Inc. Method for producing the Hpa I restriction endonuclease and methylase
    US5192676A (en) * 1991-02-05 1993-03-09 New England Biolabs, Inc. Type ii restriction endonuclease, asci, obtainable from arthrobacter species and a process for producing the same
    US5200337A (en) * 1991-10-25 1993-04-06 New England Biolabs, Inc. Type ii restriction endonuclease, apo i, obtainable from arthrobacter protophormiae and a process for producing the same
    EP0555797A1 (en) * 1992-02-10 1993-08-18 Becton, Dickinson and Company General buffer for restriction endonucleases
    US5231021A (en) * 1992-04-10 1993-07-27 Life Technologies, Inc. Cloning and expressing restriction endonucleases and modification methylases from xanthomonas
    US5248605A (en) * 1992-12-07 1993-09-28 Life Technologies, Inc. Cloning and expressing restriction endonucleases from haemophilus
    US5312746A (en) * 1993-01-08 1994-05-17 Life Technologies, Inc. Cloning and expressing restriction endonucleases and modification methylases from caryophanon
    US5334526A (en) * 1993-05-28 1994-08-02 Life Technologies, Inc. Cloning and expression of AluI restriction endonuclease
    WO1996007803A1 (en) * 1994-09-08 1996-03-14 Non-Compact, Inc. System for mounting building panels
    EP2574668A1 (en) 2005-08-04 2013-04-03 New England Biolabs, Inc. Novel restriction endonucleases, DNA encoding these endonucleases and methods for identifying new endonucleases with the same or varied specificity
    US9085798B2 (en) 2009-04-30 2015-07-21 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
    US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
    US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
    WO2011127099A1 (en) 2010-04-05 2011-10-13 Prognosys Biosciences, Inc. Spatially encoded biological assays
    WO2012139110A2 (en) 2011-04-08 2012-10-11 Prognosys Biosciences, Inc. Peptide constructs and assay systems
    GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
    WO2014145047A1 (en) 2013-03-15 2014-09-18 Prognosys Biosciences, Inc. Methods for detecting peptide/mhc/tcr binding
    WO2014210225A1 (en) 2013-06-25 2014-12-31 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
    WO2015070037A2 (en) 2013-11-08 2015-05-14 Prognosys Biosciences, Inc. Polynucleotide conjugates and methods for analyte detection
    JP6828007B2 (en) 2015-04-10 2021-02-10 スペーシャル トランスクリプトミクス アクチボラグ Spatial-identified multiplex nucleic acid analysis of biological samples
    US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
    US20220025446A1 (en) 2018-12-10 2022-01-27 10X Genomics, Inc. Methods of using master / copy arrays for spatial detection
    US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
    US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
    WO2020243579A1 (en) 2019-05-30 2020-12-03 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
    WO2021092433A2 (en) 2019-11-08 2021-05-14 10X Genomics, Inc. Enhancing specificity of analyte binding
    EP4055185A1 (en) 2019-11-08 2022-09-14 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
    CN114885610A (en) 2019-12-23 2022-08-09 10X基因组学有限公司 Methods for spatial analysis using RNA templated ligation
    US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
    US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
    US11821035B1 (en) 2020-01-29 2023-11-21 10X Genomics, Inc. Compositions and methods of making gene expression libraries
    US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
    US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
    US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
    US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
    US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
    US11768175B1 (en) 2020-03-04 2023-09-26 10X Genomics, Inc. Electrophoretic methods for spatial analysis
    ES2965354T3 (en) 2020-04-22 2024-04-12 10X Genomics Inc Methods for spatial analysis using targeted RNA deletion
    EP4153775B1 (en) 2020-05-22 2024-07-24 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
    EP4153776A1 (en) 2020-05-22 2023-03-29 10X Genomics, Inc. Spatial analysis to detect sequence variants
    WO2021242834A1 (en) 2020-05-26 2021-12-02 10X Genomics, Inc. Method for resetting an array
    AU2021283174A1 (en) 2020-06-02 2023-01-05 10X Genomics, Inc. Nucleic acid library methods
    CN116249785A (en) 2020-06-02 2023-06-09 10X基因组学有限公司 Space transcriptomics for antigen-receptor
    US12031177B1 (en) 2020-06-04 2024-07-09 10X Genomics, Inc. Methods of enhancing spatial resolution of transcripts
    WO2021252499A1 (en) 2020-06-08 2021-12-16 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
    WO2021252591A1 (en) 2020-06-10 2021-12-16 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
    WO2021263111A1 (en) 2020-06-25 2021-12-30 10X Genomics, Inc. Spatial analysis of dna methylation
    US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
    US11981960B1 (en) 2020-07-06 2024-05-14 10X Genomics, Inc. Spatial analysis utilizing degradable hydrogels
    US11981958B1 (en) 2020-08-20 2024-05-14 10X Genomics, Inc. Methods for spatial analysis using DNA capture
    US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
    US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
    EP4121555A1 (en) 2020-12-21 2023-01-25 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
    WO2022198068A1 (en) 2021-03-18 2022-09-22 10X Genomics, Inc. Multiplex capture of gene and protein expression from a biological sample
    WO2023034489A1 (en) 2021-09-01 2023-03-09 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array

    Family Cites Families (1)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    IN166864B (en) * 1985-03-01 1990-07-28 New England Biolabs Inc

    Also Published As

    Publication number Publication date
    US5002882A (en) 1991-03-26
    DE395367T1 (en) 1994-02-03
    EP0395367A1 (en) 1990-10-31
    JP2952003B2 (en) 1999-09-20
    JPH0361491A (en) 1991-03-18
    DE69032630T2 (en) 1999-03-25
    DE69032630D1 (en) 1998-10-15

    Similar Documents

    Publication Publication Date Title
    EP0395367B1 (en) Method for producing the XmaI restriction endonuclease
    US4999294A (en) Method for producing the FokI restriction endonuclease and methylase
    EP0483797B1 (en) Method for cloning and producing the Nco I restriction endonuclease
    EP0323081B1 (en) Method for producing the XbaI restriction endonuclease and methylase
    EP0343010B1 (en) Method for producing the eag I restriction endonuclease and methylase
    US4999293A (en) Method for producing the HhaI restriction endonuclease and methylase
    EP0321269B1 (en) Method for producing the HinPI restriction endonuclease and methylase
    EP0321271B1 (en) Method for producing the HgiAI restriction endonuclease and methylase
    EP0343009A2 (en) Method for producing the Nde I restriction endonuclease and methylase
    EP0388136B1 (en) Method for producing the MwoI restriction endonuclease and methylase
    US5637476A (en) Method for cloning and producing the SFII restriction endonuclease and methylase
    US5030569A (en) Method for producing the AFL II restriction endonuclease and methylase
    US4988620A (en) Method for producing the FnuDI restriction endonuclease and methylase
    US5292651A (en) Method for cloning and producing the NaeI restriction endonuclease and methylase
    EP0332406B1 (en) Method for producing the Ase I restriction endonuclease and methylase
    EP0321267B1 (en) Method for producing the AccI restriction endonuclease and methylase
    US5075232A (en) Method for producing the nlavi restriction endonuclease and methylase
    EP0314346B1 (en) Method for producing the Afl II restriction endonuclease
    EP0321268A2 (en) Method for producing the BanI restriction endonuclease and methylase
    ENDONUCLEASE Lumnen et al.
    ENDONUCLEASE Looney et al.[45] Date of Patent: Mar. 12, 1991
    ENDONUCLEASE Barsomian et al.
    ENDONUCLEASE Chen et al.

    Legal Events

    Date Code Title Description
    PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

    Free format text: ORIGINAL CODE: 0009012

    AK Designated contracting states

    Kind code of ref document: A1

    Designated state(s): DE GB

    17P Request for examination filed

    Effective date: 19901211

    17Q First examination report despatched

    Effective date: 19930902

    DET De: translation of patent claims
    APCB Communication from the board of appeal sent

    Free format text: ORIGINAL CODE: EPIDOS OBAPE

    APCB Communication from the board of appeal sent

    Free format text: ORIGINAL CODE: EPIDOS OBAPE

    APCB Communication from the board of appeal sent

    Free format text: ORIGINAL CODE: EPIDOS OBAPE

    APCB Communication from the board of appeal sent

    Free format text: ORIGINAL CODE: EPIDOS OBAPE

    APAB Appeal dossier modified

    Free format text: ORIGINAL CODE: EPIDOS NOAPE

    GRAG Despatch of communication of intention to grant

    Free format text: ORIGINAL CODE: EPIDOS AGRA

    GRAG Despatch of communication of intention to grant

    Free format text: ORIGINAL CODE: EPIDOS AGRA

    GRAH Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOS IGRA

    GRAH Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOS IGRA

    GRAA (expected) grant

    Free format text: ORIGINAL CODE: 0009210

    AK Designated contracting states

    Kind code of ref document: B1

    Designated state(s): DE GB

    DX Miscellaneous (deleted)
    REF Corresponds to:

    Ref document number: 69032630

    Country of ref document: DE

    Date of ref document: 19981015

    PLBE No opposition filed within time limit

    Free format text: ORIGINAL CODE: 0009261

    STAA Information on the status of an ep patent application or granted ep patent

    Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

    26N No opposition filed
    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: IF02

    APAH Appeal reference modified

    Free format text: ORIGINAL CODE: EPIDOSCREFNO

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: GB

    Payment date: 20090312

    Year of fee payment: 20

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: DE

    Payment date: 20090430

    Year of fee payment: 20

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: PE20

    Expiry date: 20100424

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: GB

    Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

    Effective date: 20100424

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: DE

    Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

    Effective date: 20100425